120 related articles for article (PubMed ID: 12637104)
1. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies.
Rodríguez-Ibáñez M; Nalda-Molina R; Montalar-Montero M; Bermejo MV; Merino V; Garrigues TM
Eur J Pharm Biopharm; 2003 Mar; 55(2):241-6. PubMed ID: 12637104
[TBL] [Abstract][Full Text] [Related]
2. Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepafloxacin.
Rodríguez-Ibáñez M; Sánchez-Castaño G; Montalar-Montero M; Garrigues TM; Bermejo M; Merino V
Int J Pharm; 2006 Jan; 307(1):33-41. PubMed ID: 16257153
[TBL] [Abstract][Full Text] [Related]
3. Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells.
Lowes S; Simmons NL
Br J Pharmacol; 2002 Mar; 135(5):1263-75. PubMed ID: 11877335
[TBL] [Abstract][Full Text] [Related]
4. Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.
Yamaguchi H; Yano I; Saito H; Inui K
Pharm Res; 2004 Feb; 21(2):330-8. PubMed ID: 15032316
[TBL] [Abstract][Full Text] [Related]
5. Kinetic modelling of the intestinal transport of sarafloxacin. Studies in situ in rat and in vitro in Caco-2 cells.
Fernandez-Teruel C; Gonzalez-Alvarez I; Casabó VG; Ruiz-Garcia A; Bermejo M
J Drug Target; 2005 Apr; 13(3):199-212. PubMed ID: 16036308
[TBL] [Abstract][Full Text] [Related]
6. In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with in vitro results.
González-Alvarez I; Fernández-Teruel C; Casabó-Alós VG; Garrigues TM; Polli JE; Ruiz-García A; Bermejo M
Biopharm Drug Dispos; 2007 Jul; 28(5):229-39. PubMed ID: 17410527
[TBL] [Abstract][Full Text] [Related]
7. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier.
Tamai I; Yamashita J; Kido Y; Ohnari A; Sai Y; Shima Y; Naruhashi K; Koizumi S; Tsuji A
J Pharmacol Exp Ther; 2000 Oct; 295(1):146-52. PubMed ID: 10991972
[TBL] [Abstract][Full Text] [Related]
8. Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates.
Dautrey S; Felice K; Petiet A; Lacour B; Carbon C; Farinotti R
Br J Pharmacol; 1999 Aug; 127(7):1728-34. PubMed ID: 10455332
[TBL] [Abstract][Full Text] [Related]
9. Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux.
Sikri V; Pal D; Jain R; Kalyani D; Mitra AK
Am J Ther; 2004; 11(6):433-42. PubMed ID: 15543082
[TBL] [Abstract][Full Text] [Related]
10. Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.
Naruhashi K; Tamai I; Inoue N; Muraoka H; Sai Y; Suzuki N; Tsuji A
J Pharm Pharmacol; 2001 May; 53(5):699-709. PubMed ID: 11370709
[TBL] [Abstract][Full Text] [Related]
11. Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats.
Naruhashi K; Tamai I; Inoue N; Muraoka H; Sai Y; Suzuki N; Tsuji A
Antimicrob Agents Chemother; 2002 Feb; 46(2):344-9. PubMed ID: 11796340
[TBL] [Abstract][Full Text] [Related]
12. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.
Yamaguchi H; Yano I; Hashimoto Y; Inui KI
J Pharmacol Exp Ther; 2000 Oct; 295(1):360-6. PubMed ID: 10992002
[TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells.
Cavet ME; West M; Simmons NL
Br J Pharmacol; 1997 Aug; 121(8):1567-78. PubMed ID: 9283689
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
Yamaguchi H; Yano I; Saito H; Inui K
J Pharmacol Exp Ther; 2002 Mar; 300(3):1063-9. PubMed ID: 11861816
[TBL] [Abstract][Full Text] [Related]
15. Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers.
Ruiz-García A; Lin H; Plá-Delfina JM; Hu M
J Pharm Sci; 2002 Dec; 91(12):2511-9. PubMed ID: 12434394
[TBL] [Abstract][Full Text] [Related]
16. Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats.
Rubinstein E; Dautrey S; Farinoti R; St Julien L; Ramon J; Carbon C
Antimicrob Agents Chemother; 1995 Jan; 39(1):99-102. PubMed ID: 7695338
[TBL] [Abstract][Full Text] [Related]
17. Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5.
Arakawa H; Shirasaka Y; Haga M; Nakanishi T; Tamai I
Biopharm Drug Dispos; 2012 Sep; 33(6):332-41. PubMed ID: 22899169
[TBL] [Abstract][Full Text] [Related]
18. Ciprofloxacin permeability and its active secretion through rat small intestine in vitro.
Zakelj S; Sturm K; Kristl A
Int J Pharm; 2006 Apr; 313(1-2):175-80. PubMed ID: 16529884
[TBL] [Abstract][Full Text] [Related]
19. Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2.
Yamaguchi H; Yano I; Saito H; Inui K
Eur J Pharmacol; 2001 Nov; 431(3):297-303. PubMed ID: 11730721
[TBL] [Abstract][Full Text] [Related]
20. Distribution characteristics of levofloxacin and grepafloxacin in rat kidney.
Ito T; Yano I; Masuda S; Hashimoto Y; Inui K
Pharm Res; 1999 Apr; 16(4):534-9. PubMed ID: 10227708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
